Meena B. Bansal

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

Naga Chalasani, Herbert L. Bonkovsky, Robert J. Fontana et al. · Gastroenterology · 2015 · 872 citations · Full text

Dilin Prospective Study, Hepatology, Medicine +10

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 733 citations

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +10

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Marc Bourlière, Stuart C. Gordon, Steven L. Flamm et al. · New England Journal of Medicine · 2017 · 558 citations